Inflammatory markers and adiponectin plasma level in patients with type 2 diabetes;Stȩżenie markerów zapalenia i adyponektyny w surowicy u chorych na cukrzycȩ typu 2

Polskie Archiwum Medycyny Wewnetrznej

Volumn 114, Issue 1, 2005, Pages 652-657

  Zurawska Kliś, Monika ^a,b   Drzewoski, Józef ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Oddzia em Farmakologii Klinicznej   (Poland)

Author keywords

Adiponectin; Inflammatory markers; Insulin resistance; Obesity; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 6; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; MIDDLE AGED;

ADIPONECTIN; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646451256     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Tanaka T., Itoh H., Doi K. i wsp.: Down regulation of peroxisome proliferators-activated receptory expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia, 1999, 42, 702.
2. Sen Liu L., Spelleken M., Rohrig K. i wsp.: Tumor necrosis factor-α acutely inhibits insulin signaling in human adipocytes. Diabetes, 1998, 515.
3. Uysal T.K., Wiesbrock S.M., Marino M.W. i wsp.: Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature, 1997, 389, 610.
4. Esposito K., Nappo F., Marfella R. i wsp.: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Circulation, 2002, 106, 2067.
5. Blüher M., Kratzsch J., Paschke R. i wsp.: Plasma levels of tumor necrosis factor-α, angiotensin II, growth hormone, and IGF-1 are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care, 2001, 24, 328.
6. Müller S., Martin S., Koening W. i wsp.: Impaired glucose tolerance is associated with increased concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-α or its receptors. Diabetologia, 2002, 45, 805.
7. Morohoshi M., Fujisawa K., Uchimur I. i wsp.: Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes, 1996, 45, 954.
8. Bastard J.P., Maachi M., Van Nhieu J.T. i wsp.: Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2084.
9. Pradhan A.D., Manson J.E., Rifai N. i wsp.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 2001, 286, 327.
10. Krakoff J., Funahashi T., Stehouver CD. i wsp.: Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indians. Diabetes Care, 2003, 26, 1745,
11. Fernandez-Real J.M., Broch M., Vendrell J. i wsp.: Interleukin 6 gene polymorphism and insulin sensitivity. Diabetes, 2000, 49, 517.
12. Leinonen E., Hurt-Camejo E., Wiklund O. i wsp.: Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis, 2003, 166, 287.
13. Pellme F., Smith U., Funahashi T. i wsp.: Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients, Diabetes, 2003, 52, 1182.
14. Hotta K., Funahashi T., Bodkin N.L. i wsp.: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys, Diabetes 2001, 50, 1126.
15. Hanley A., Connelly P., Harris S. i wsp.: Adiponectin in a native canadian population experiencing rapid epidemiological transition, Diabetes Care, 2003, 26, 3219.
16. Stefan N., Vozarowa B., Funahashi T. i wsp.: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans, Diabetes, 2002, 51, 1884.
17. Weyer C., Funahashi T., Tanaka S. i wsp.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hiperinsulinemia, J. Clin. Endocrinol. Metab., 2001, 86, 1930.
18. Yu J.G., Javorschi S,. Hevener A.L. i wsp.: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and type 2 diabetic subjects, Diabetes, 2002, 51, 2968.
19. Yang W.S., Lee W.J., Funahashi T. i wsp.: Plasma adiponectin level in overweight and obese Asians, Obes., Res., 2002, 10, 1104.
20. Combs T.P., Berg A.H., Obici S. i wsp.: Endogenous glucose production is inhibited by the adipose-derived protein Acrp 30, J. Clin. Invest, 2001, 108, 1875.
21. Stefan N., Stumvoli M., Vozarova B. i wsp.: Plasma adiponectin and endogenous glucose production in humans, Diabetes Care 2003, 3315.
22. Bełtowski J.: Adiponectin and resistin - new hormones of white adipose tissue, Med. Sci. Monit., 2003, 9, RA55.
23. Hattori Y., Suzuki M., Hattori S. i wsp.: Globular adiponectin upregulates nitric oxide production in vascular endothelial cells, Diabetologia, 2003, 46, 1543.
24. Snehalatha Ch., Mukesh B., Simon M. i wsp.: Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians, Dibetes Care, 2003, 26, 3226.
25. Adamczak M., Wiecek A., Funahashi T. i wsp.: Decreased plasma adiponectin concentration in patients with essential hypertension. Am. J. Hypertens., 2003, 16, 72.